{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:41:04Z","timestamp":1791837664637,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110931","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:23:50Z","timestamp":1746905030000},"page":"110931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety"],"prefix":"10.1016","volume":"208","author":[{"given":"Kate\u0159ina","family":"D\u011bde\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-5583","authenticated-orcid":false,"given":"Michal","family":"Andrlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"M\u00f3cikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Kalisk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zapletalov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Kube\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-4482","authenticated-orcid":false,"given":"Sarah","family":"Al-Hamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-7488","authenticated-orcid":false,"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Ntentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-0101","authenticated-orcid":false,"given":"Vladim\u00edr","family":"Vondr\u00e1\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Ondrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Markov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u013dubica","family":"Gah\u00e9rov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leka\u00e1","family":"Mohammadov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9861-3117","authenticated-orcid":false,"given":"V\u00edt","family":"Proch\u00e1zka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Michalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"S\u00fdkorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4351-4953","authenticated-orcid":false,"given":"Juraj","family":"\u010eura\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ko\u0159en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u011bj","family":"Navr\u00e1til","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Va\u0159ejkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Dole\u017eal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Prausov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110931_b0005","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0010","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.radonc.2025.110931_b0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.110931_b0025","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110931_b0030","doi-asserted-by":"crossref","unstructured":"Galper SL, Yu JB, Mauch PM et al Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011 Jan 13;117(2):412-8. doi: 10.1182\/blood-2010-06-291328. Epub 2010 Sep 21. PMID: 20858859.","DOI":"10.1182\/blood-2010-06-291328"},{"key":"10.1016\/j.radonc.2025.110931_b0035","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.110931_b0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0050","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110931_b0055","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110931_b0060","doi-asserted-by":"crossref","unstructured":"Borchmann P, Ferdinandus J, Schneider G et al; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016\/S0140-6736(24)01315-1. Epub 2024 Jul 3. PMID: 38971175.","DOI":"10.1016\/S0140-6736(24)01315-1"},{"key":"10.1016\/j.radonc.2025.110931_b0065","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110931_b0070","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110931_b0075","doi-asserted-by":"crossref","unstructured":"Ansell SM, Radford J, Connors JM et al. ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056\/NEJMoa2206125. Epub 2022 Jul 13. PMID: 35830649.","DOI":"10.1056\/NEJMoa2206125"},{"key":"10.1016\/j.radonc.2025.110931_b0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0085","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 MPE, Carde P, Viviani S et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Med. 2020 Sep;9(18):6565-6575. doi: 10.1002\/cam4.3298. Epub 2020 Jul 25. PMID: 32710498; PMCID: PMC7520354.","DOI":"10.1002\/cam4.3298"},{"key":"10.1016\/j.radonc.2025.110931_b0090","doi-asserted-by":"crossref","unstructured":"Maraldo MV, Giusti F, Vogelius IR, et al. European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015 Nov;2(11):e492-502. doi: 10.1016\/S2352-3026(15)00153-2. Epub 2015 Oct 22. PMID: 26686259.","DOI":"10.1016\/S2352-3026(15)00153-2"},{"key":"10.1016\/j.radonc.2025.110931_b0095","doi-asserted-by":"crossref","unstructured":"Neppelenbroek SIM, Geurts YM, Aleman BMP et al. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200\/JCO.23.01386. Epub 2024 Feb 15. PMID: 38359378; PMCID: PMC11191044.","DOI":"10.1200\/JCO.23.01386"},{"key":"10.1016\/j.radonc.2025.110931_b0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djab133","article-title":"Longitudinal changes in cognitive function in a nationwide cohort study of patients with lymphoma treated with chemotherapy","volume":"114","author":"Janelsins","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.110931_b0105","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093\/annonc\/mdy080. PMID: 29796651.","DOI":"10.1093\/annonc\/mdy080"},{"key":"10.1016\/j.radonc.2025.110931_b0110","doi-asserted-by":"crossref","unstructured":"Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, Andr\u00e9 M. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC\/LYSA\/FIL H10 Trial for Localized Hodgkin Lymphoma. J Clin Oncol. 2024 Jan 1;42(1):19-25. doi: 10.1200\/JCO.23.01745. Epub 2023 Nov 15. PMID: 37967311; PMCID: PMC10730029.","DOI":"10.1200\/JCO.23.01745"},{"key":"10.1016\/j.radonc.2025.110931_b0115","doi-asserted-by":"crossref","unstructured":"Rechner LA, Maraldo MV, Vogelius IR, Zhu XR, Dabaja BS, Brodin NP, Petersen PM, Specht L, Aznar MC. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and\/or deep inspiration breath hold. Radiother Oncol. 2017 Oct;125(1):41-47. doi: 10.1016\/j.radonc.2017.07.033. Epub 2017 Aug 30. PMID: 28838605; PMCID: PMC5844950.","DOI":"10.1016\/j.radonc.2017.07.033"},{"key":"10.1016\/j.radonc.2025.110931_b0120","doi-asserted-by":"crossref","unstructured":"K\u00f6nig L, Haering P, Lang C, Splinter M, von Nettelbladt B, Weykamp F, Hoegen P, Lischalk JW, Herfarth K, Debus J, H\u00f6rner-Rieber J. Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Front Oncol. 2020 Jul 7;10:989. doi: 10.3389\/fonc.2020.00989. PMID: 32733794; PMCID: PMC7358352.","DOI":"10.3389\/fonc.2020.00989"},{"key":"10.1016\/j.radonc.2025.110931_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2008.12.048","article-title":"Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy","volume":"75","author":"Chera","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canrad.2015.11.002","article-title":"Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy","volume":"20","author":"Horn","year":"2016","journal-title":"Cancer Radiothrapie"},{"key":"10.1016\/j.radonc.2025.110931_b0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the particle therapy cooperative group (PTCOG) Lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0145","doi-asserted-by":"crossref","unstructured":"Dabaja BS, Hoppe BS, Plastaras JP et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018 Oct 18;132(16):1635-1646. doi: 10.1182\/blood-2018-03-837633. Epub 2018 Aug 14. Erratum in: Blood. 2019 Mar 21;133(12):1384-1385. doi: 10.1182\/blood-2019-02-900738. PMID: 30108066; PMCID: PMC6212652.","DOI":"10.1182\/blood-2019-02-900738"},{"key":"10.1016\/j.radonc.2025.110931_b0150","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0155","doi-asserted-by":"crossref","unstructured":"Ntentas G, Dedeckova K, Andrlik M et al. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):913-925. doi: 10.1016\/j.ijrobp.2021.10.151. Epub 2021 Nov 9. PMID: 34762970; PMCID: PMC8865523.","DOI":"10.1016\/j.ijrobp.2021.10.151"},{"key":"10.1016\/j.radonc.2025.110931_b0160","doi-asserted-by":"crossref","unstructured":"Ntentas G, Dedeckova K, Andrlik M, Aznar MC, George B, Kube\u0161 J, Darby SC, Cutter DJ. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Pract Radiat Oncol. 2019 May;9(3):179-187. doi: 10.1016\/j.prro.2019.01.006. Epub 2019 Jan 29. PMID: 30708133; PMCID: PMC6493042.","DOI":"10.1016\/j.prro.2019.01.006"},{"key":"10.1016\/j.radonc.2025.110931_b0165","doi-asserted-by":"crossref","unstructured":"Houlihan OA, Ntentas G, Cutter DJ et al. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma. Clin Transl Oncol. 2023 May;25(5):1368-1377. doi: 10.1007\/s12094-022-03034-z. Epub 2022 Dec 31. PMID: 36585562; PMCID: PMC10119211.","DOI":"10.1007\/s12094-022-03034-z"},{"key":"10.1016\/j.radonc.2025.110931_b0170","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0175","doi-asserted-by":"crossref","unstructured":"K\u00f6nig L, Bougatf N, H\u00f6rner-Rieber J et al. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlenther Onkol. 2019 Jul;195(7):677-687. English. doi: 10.1007\/s00066-019-01460-7. Epub 2019 Apr 10. PMID: 30972453.","DOI":"10.1007\/s00066-019-01460-7"},{"key":"10.1016\/j.radonc.2025.110931_b0180","doi-asserted-by":"crossref","unstructured":"Tringale KR, Modlin LA, Sine K et al. Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients. Radiother Oncol. 2022 Mar;168:46-52. doi: 10.1016\/j.radonc.2022.01.016. Epub 2022 Jan 29. PMID: 35101461; PMCID: PMC9446376.","DOI":"10.1016\/j.radonc.2022.01.016"},{"key":"10.1016\/j.radonc.2025.110931_b0185","unstructured":"https:\/\/www.lymphoma.cz\/pro-pracovniky-ve-zdravotnictvi\/8-lecebna-doporuceni\/)."},{"key":"10.1016\/j.radonc.2025.110931_b0190","unstructured":"https:\/\/www.hodgkin.cz\/registr-pacientu\/."},{"key":"10.1016\/j.radonc.2025.110931_b0195","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0200","doi-asserted-by":"crossref","unstructured":"Specht L, Yahalom J, Illidge T et al. ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62. doi: 10.1016\/j.ijrobp.2013.05.005. Epub 2013 Jun 18. PMID: 23790512.","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"10.1016\/j.radonc.2025.110931_b0205","doi-asserted-by":"crossref","unstructured":"Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8. doi: 10.1016\/j.ijrobp.2009.10.058. Epub 2010 Apr 24. PMID: 20421148; PMCID: PMC2937165.","DOI":"10.1016\/j.ijrobp.2009.10.058"},{"key":"10.1016\/j.radonc.2025.110931_b0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy","volume":"53","author":"Paganetti","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0215","article-title":"Proton radiation therapy after chemotherapy in the management of aggressive mediastinal non-hodgkin lymphomas: a particle therapy cooperative group lymphoma subcommittee collaboration","volume":"8","author":"Baron","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0220","doi-asserted-by":"crossref","unstructured":"Prasanna PG, Rawojc K, Guha C et al. Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1325-1340. doi: 10.1016\/j.ijrobp.2021.02.043. Epub 2021 Feb 25. PMID: 33640423; PMCID: PMC8496269.","DOI":"10.1016\/j.ijrobp.2021.02.043"},{"key":"10.1016\/j.radonc.2025.110931_b0225","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.2147\/OTT.S220730","article-title":"Proton therapy for lymphomas: current state of the art","volume":"1","author":"Ricardi","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.radonc.2025.110931_b0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13014-019-1432-8","article-title":"Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness","volume":"14","author":"Tseng","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1120\/jacmp.v16i5.5386","article-title":"Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential","volume":"16","author":"Toltz","year":"2015","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2025.110931_b0240","article-title":"Proton linear energy transfer and variable relative biological effectiveness for adolescent patients with Hodgkin lymphoma","volume":"5","author":"Rechner","year":"2023","journal-title":"BJR Open"},{"key":"10.1016\/j.radonc.2025.110931_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2022.10.003","article-title":"Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations","volume":"177","author":"Patel","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0250","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3390\/cancers13153744","article-title":"Development and implementation of proton therapy for hodgkin lymphoma: challenges and perspectives","volume":"13","author":"Loap","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110931_b0255","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/0284186X.2022.2084639","article-title":"Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy","volume":"61","author":"Loap","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110019","article-title":"Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy","volume":"190","author":"Cortiula","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0265","article-title":"Proton therapy reduces the effective dose to immune cells in mediastinal hodgkin lymphoma patients","volume":"20","author":"Loap","year":"2024","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2025.110931_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103923","article-title":"Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy","volume":"182","author":"Maaroufi","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2025.110931_b0275","doi-asserted-by":"crossref","unstructured":"Br\u00f6ckelmann, P, B\u00fchnen I, Zijlstra J et al. S203: Abscopal effect of radiotherapy and nivolumab in relapsed or refractory hodgkin lymphoma: pre-planned interim analysis of the international ghsg phase ii aern triaL. HemaSphere 6:p 104-105, June 2022. | DOI: 10.1097\/01.HS9.0000843704.08384.3e.","DOI":"10.1097\/01.HS9.0000843704.08384.3e"},{"key":"10.1016\/j.radonc.2025.110931_b0280","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.clml.2021.09.005","article-title":"'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy","volume":"22","author":"Guerini","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.radonc.2025.110931_b0285","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.3390\/ijms21218151","article-title":"Immunomodulatory effects of radiotherapy","volume":"21","author":"Kumari","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2025.110931_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110030","article-title":"The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC","volume":"190","author":"Friedes","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110931_b0295","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","article-title":"Severe lymphopenia during chemoradiation therapy for esophageal cancer: comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy","volume":"118","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:59:41Z","timestamp":1753775981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":59,"alternative-id":["S0167814025002269"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110931","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110931"}}